Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GYRE

Gyre Therapeutics Inc

Dec 12 • 12:43PM ET

10.06

Dollar change +0.04
Percentage change 0.40	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN VRTX REGN GILD BMRN BIIB INCY NBIX EXEL ACAD

| Held by: VXF IWM SCHA IWN VTWO ITOT SCHB AVSC VTWV RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-17.57	Insider Own	74.71%	Shs Outstand	85.77M	Perf Week	-3.87%
Market Cap	863.37M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.01%	Shs Float	21.71M	Perf Month	-37.16%
Income	-44.24M	PEG	-	EPS next Q	-	Inst Own	1.88%	Short Float	2.53%	Perf Quarter	-25.54%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	27.51%	Short Ratio	7.45	Perf Half Y	-8.88%
Book/sh	0.74	P/B	13.66	EPS next Y	-	ROA	-215.90%	Short Interest	0.55M	Perf Year	-50.02%
Cash/sh	0.29	P/C	34.41	EPS next 5Y	-	ROE	-269.01%	52W Range	8.26 - 30.40	Perf YTD	-60.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.82%	ROI	-68.83%	52W High	-66.91%	Beta	1.93
Dividend TTM	-	Quick Ratio	3.29	Sales past 5Y	227.98%	Gross Margin	-	52W Low	21.79%	ATR (14)	1.12
Dividend Ex-Date	Jan 13, 2023	Current Ratio	3.72	EPS Y/Y TTM	-411.67%	Oper. Margin	-	RSI (14)	37.32	Volatility	11.28% 10.97%
Employees	4	Debt/Eq	0.03	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	2.00	Target Price	45.00
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	101.34%	Payout	-	Rel Volume	2.21	Prev Close	10.02
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	73.70K	Price	10.06
SMA20	-13.62%	SMA50	-23.55%	SMA200	-27.00%	Trades		Volume	84,745	Change	0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-21	Resumed	Stephens	Overweight	$18 → $19
Feb-10-21	Initiated	Piper Sandler	Overweight	$15
May-21-20	Initiated	Raymond James	Outperform	$20
Jan-04-19	Initiated	Oppenheimer	Outperform	$24
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy	$19 → $49
Feb-09-18	Reiterated	Chardan Capital Markets	Buy	$37.50 → $75
Feb-09-18	Reiterated	Chardan Capital Markets	Buy	$10 → $75
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy	$19
Jun-12-17	Initiated	Chardan Capital Markets	Buy	$10
Jun-06-17	Initiated	Ladenburg Thalmann	Buy	$11
Jun-30-16	Initiated	Rodman & Renshaw	Buy	$3.50

Show Previous Ratings

Nov-13-24 06:00AM	Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update (GlobeNewswire) -9.56%
Oct-22-24 04:05PM	Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis (GlobeNewswire)
Oct-01-24 04:05PM	Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference (GlobeNewswire)
Sep-04-24 04:05PM	Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 06:00AM	Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Aug-09-24 07:00AM	Gyre Therapeutics to Present at Sidoti Virtual Investor Conference (GlobeNewswire)
Aug-08-24 04:05PM	Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors (GlobeNewswire)
Jul-02-24 04:05PM	Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia (GlobeNewswire)
Jun-18-24 04:05PM	Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology (GlobeNewswire) -6.33%
May-30-24 04:05PM	Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire) +9.13%
May-28-24 04:05PM	Gyre Therapeutics Announces Expected Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) -15.35%
May-09-24 04:10PM	Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-28-24 05:32AM	Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress (GuruFocus.com)
Mar-26-24 06:32AM	Gyre Therapeutics Posts Loss In 2023 (RTT News)
06:00AM	Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Mar-21-24 07:00AM	Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum (GlobeNewswire)
Dec-15-23 09:04AM	Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding (PR Newswire) +9.91%
Nov-13-23 07:00AM	Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting (GlobeNewswire)
Oct-30-23 12:00PM	Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split (GlobeNewswire)
Aug-23-23 12:36PM	Is Catalyst Biosciences (CBIO) Significantly Overvalued? (GuruFocus.com) +11.72%
Apr-03-23 09:01AM	Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 months (Simply Wall St.)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Feb-28-23 08:00AM	Catalyst Biosciences Provides Corporate Update (GlobeNewswire) +23.75%
Dec-27-22 07:00AM	Catalyst Biosciences Completes First Steps in Reverse Merger Plan (GlobeNewswire)
Nov-16-22 05:05AM	Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021) (Simply Wall St.)
Sep-19-22 09:43AM	Bullish insiders at Catalyst Biosciences, Inc. (NASDAQ:CBIO) loaded up on US$1.2m of stock earlier this year (Simply Wall St.)
Sep-01-22 04:05PM	Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share (GlobeNewswire)
Aug-25-22 08:00AM	Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share (GlobeNewswire)
Aug-23-22 07:11AM	Catalyst Biosciences (NASDAQ:CBIO) investors are sitting on a loss of 71% if they invested three years ago (Simply Wall St.)
Aug-19-22 08:00AM	Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation (GlobeNewswire)
04:05PM	Loading…
Aug-15-22 04:05PM	Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results (GlobeNewswire)
Aug-11-22 06:00AM	JDS1, LLC Terminates Proxy Contest at Catalysts 2022 Annual Meeting (Business Wire)
Aug-10-22 12:46PM	Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board (GlobeNewswire)
Aug-03-22 08:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote FOR All of the Companys Nominees on the WHITE Proxy Card (GlobeNewswire)
Aug-01-22 08:30AM	Catalyst Biosciences Publishes New Investor Presentation (GlobeNewswire)
07:30AM	Catalyst Biosciences Announces Support from Largest Single Stockholder (GlobeNewswire)
Jul-22-22 12:21PM	JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders (Business Wire)
Jul-19-22 08:00AM	Catalyst Biosciences Sends Letter to Stockholders (GlobeNewswire)
Jul-14-22 09:40AM	Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-06-22 08:00AM	Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling (GlobeNewswire)
Jun-29-22 08:00AM	Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders (GlobeNewswire) +13.25%
Jun-28-22 09:40AM	Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year? (Zacks) -5.03%
May-26-22 11:03AM	The Petri Dish: NIH gives $68M to Pfizer-partnered AI startup (American City Business Journals) -22.38%
May-23-22 09:57AM	Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex (Benzinga) +234.21%
08:30AM	Catalyst Biosciences Sells Complement Portfolio for $60 Million (GlobeNewswire)
May-09-22 08:30AM	Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results (GlobeNewswire) -11.42%
Apr-08-22 09:57AM	Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely (Simply Wall St.) -7.26%
Mar-31-22 08:00AM	Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-15-22 05:00PM	Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIOs Complement Portfolio in Ophthalmology (GlobeNewswire) +9.50%
Feb-17-22 08:00AM	Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives (GlobeNewswire) +6.40%
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... (GuruFocus.com)
Jan-25-22 08:00AM	Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency (GlobeNewswire) -7.05%
Jan-12-22 12:00PM	Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-20-21 07:51PM	Penny Stocks to Buy Using Technical Analysis for January 2022 (Investopedia)
Dec-11-21 11:59AM	Timothy P. Lynchs Stonepine Capital Portfolio: Top 10 Healthcare Stocks (Insider Monkey)
Nov-22-21 08:00AM	Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-12-21 09:54AM	Catalyst Biosciences Down 40% After Announcing MarzAA Development Halt (Investing.com) -41.84%
09:24AM	What Is Happening With Catalyst Biosciences Shares Today? (Benzinga)
07:00AM	Catalyst Biosciences Announces Change in Corporate Strategy (GlobeNewswire)
Oct-29-21 08:00AM	Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences (GlobeNewswire)
Oct-28-21 03:05PM	Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) +5.03%
Oct-13-21 04:05PM	Catalyst Biosciences Announces Chief Financial Officer Transition (GlobeNewswire)
Sep-28-21 04:01PM	FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency (GlobeNewswire) -8.44%
Sep-24-21 08:00AM	Catalyst Biosciences to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-17-21 07:06AM	Here's Why We're A Bit Worried About Catalyst Biosciences' (NASDAQ:CBIO) Cash Burn Situation (Simply Wall St.)
Sep-15-21 08:00AM	Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital (GlobeNewswire) +5.64%
Sep-09-21 08:00AM	Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics (GlobeNewswire)
Sep-08-21 08:00AM	Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors (GlobeNewswire)
Aug-05-21 10:55AM	Catalyst Biosciences, Inc. (CBIO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-29-21 03:05PM	Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-21 08:00AM	Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies (GlobeNewswire)
Jul-19-21 04:01PM	Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress (GlobeNewswire)
02:09AM	Reflecting on Catalyst Biosciences' (NASDAQ:CBIO) Share Price Returns Over The Last Five Years (Simply Wall St.)
Jul-14-21 08:00AM	Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company (GlobeNewswire) -6.74%
Jul-06-21 08:00AM	Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis (GlobeNewswire)
Jul-01-21 08:00AM	Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs (GlobeNewswire)
Jun-28-21 08:45AM	Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA (Benzinga)
08:00AM	Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency (GlobeNewswire)
Jun-21-21 06:00AM	KBR to Provide Engineering & Technical Services for NATO Allies Patriot System (PR Newswire)
Jun-10-21 08:00AM	Catalyst Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-20-21 02:57AM	What Type Of Shareholders Own The Most Number of Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares? (Simply Wall St.)
May-18-21 08:00AM	Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra (GlobeNewswire)
May-13-21 08:00AM	Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit (GlobeNewswire)
May-06-21 12:19PM	Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat? (Zacks)
09:23AM	Is a Surprise Coming for Catalyst Biosciences (CBIO) This Earnings Season? (Zacks)
09:15AM	Catalyst Biosciences, Inc. (CBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update (GlobeNewswire)
May-05-21 12:29PM	What's in Store for Select Medical (SEM) Earnings in Q1? (Zacks)
08:00AM	Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors (GlobeNewswire)
Apr-28-21 08:00AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Catalyst Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (ACCESSWIRE)
Apr-21-21 11:43AM	2 Strong Buy Penny Stocks That Could Deliver Massive Returns (TipRanks) +9.45%
Apr-19-21 08:00AM	Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the American Society of Hematology (GlobeNewswire)
Apr-12-21 08:00AM	Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders (GlobeNewswire)
Apr-07-21 04:05PM	Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-21 04:20AM	Will Catalyst Biosciences (NASDAQ:CBIO) Spend Its Cash Wisely? (Simply Wall St.)
Mar-04-21 08:00AM	Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update (GlobeNewswire) -5.91%
Feb-18-21 08:00AM	Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference (GlobeNewswire) -5.87%
Feb-11-21 04:01PM	Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock (GlobeNewswire)
Feb-10-21 10:05AM	Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021 (Benzinga)

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
USMAN NASSIM	Director	Jun 28 '24	Option Exercise	6.93	3,452	23,922	5,088	Jul 01 06:00 PM
USMAN NASSIM	Director	Jun 28 '24	Sale	12.00	3,452	41,438	1,636	Jul 01 06:00 PM
USMAN NASSIM	Director	May 01 '24	Option Exercise	6.93	20,000	138,600	21,636	May 02 06:19 PM
USMAN NASSIM	Director	May 01 '24	Sale	14.13	20,000	282,577	1,636	May 02 06:19 PM
USMAN NASSIM	Director	Apr 01 '24	Option Exercise	6.93	20,000	138,600	21,636	Apr 03 04:01 PM
USMAN NASSIM	Director	Apr 01 '24	Sale	16.15	20,000	323,000	1,636	Apr 03 04:01 PM
USMAN NASSIM	Director	Mar 15 '24	Option Exercise	6.93	20,000	138,600	21,636	Mar 19 04:47 PM
USMAN NASSIM	Director	Mar 15 '24	Sale	17.26	20,000	345,200	1,636	Mar 19 04:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GYRE

Gyre Therapeutics Inc

Upgrade your FINVIZ experience